YH32367

About Yuhan

Founded in 1926, Yuhan Corporation is one of South Korea's most established and innovative pharmaceutical companies, operating with a dual focus on a profitable commercial business and a cutting-edge R&D pipeline. The company has achieved significant milestones, including the successful development and out-licensing of its EGFR inhibitor, lazertinib, to Janssen, and the commercialization of its leading diabetes franchise. Yuhan's strategy is built on internal R&D in oncology and immunology, strategic in-licensing, and global partnerships to expand its reach beyond the Korean market.

Therapeutic Areas

Other HER2-positive Solid Tumors Drugs